Science Explorer Back to mapMap
Discussion
Institution · Dr Willmar Schwabe (Germany)

Most cited papers from Dr Willmar Schwabe (Germany)

Dr Willmar Schwabe (Germany)

What are the most cited papers from Dr Willmar Schwabe (Germany)?

The most cited paper from Dr Willmar Schwabe (Germany) is "Hyperforin as a possible antidepressant component of hypericum extracts" (Shyam S Chatterjee, S.K. Bhattacharya, Meinolf Wonnemann et al., 1998), with 446 citations. Next come "Incidence and prognostic significance of fever following intracerebral hemorrhage" (379) and "Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research—The ConPhyMP—Guidelines12" (371).

Showing 50 of 59 papers. Every paper with more than 89 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Hyperforin as a possible antidepressant component of hypericum extracts Shyam S Chatterjee, S.K. Bhattacharya, Meinolf Wonnemann et al. · Life Sciences Jul 1998 446
2 Incidence and prognostic significance of fever following intracerebral hemorrhage Štefan Schwarz, Kurt Häfner, Alfred A. Aschoff et al. · Neurology 25 Jan 2000 379
3 Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research—The ConPhyMP—Guidelines12 Michael Heinrich, Banaz Jalil, Mona Abdel‐Tawab et al. · Frontiers in Pharmacology Open access 13 Sep 2022 371
4 Proof of Efficacy of the Ginkgo Biloba Special Extract EGb 761 in Outpatients Suffering from Mild to Moderate Primary Degenerative Dementia of the Alzheimer Type or Multi-infarct Dementia S. Kanowski, Wolfgang R. Herrmann, K. Stephan et al. · Pharmacopsychiatry Mar 1996 370
5 St. John's Wort in Mild to Moderate Depression: The Relevance of Hyperforin for the Clinical Efficacy G. Laakmann, Cornelius Schüle, Thomas C. Baghai et al. · Pharmacopsychiatry Jun 1998 341
6 Combining different phases in the development of medical treatments within a single trial Péter Bauer, Meinhard Kieser · Statistics in Medicine 30 Jul 1999 284
7 A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder Helmut Woelk, Sandra Schläfke · Phytomedicine 7 Dec 2009 238
8 On the Use of the Upper Confidence Limit for the Variance from a Pilot Sample for Sample Size Determination Meinhard Kieser, Gernot Wassmer · Biometrical Journal 1996 222
9 Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine Armin Szegedi, Ralf Kohnen, Angelika Dienel et al. · BMJ Open access 11 Feb 2005 221
10 Lavender oil preparation Silexan is effective in generalized anxiety disorder – a randomized, double-blind comparison to placebo and paroxetine Siegfried F. Kasper, Markus Gastpar, Walter E Müller et al. · The International Journal of Neuropsychopharmacology 23 Jan 2014 220
11 Oral Bioavailability of Hyperforin from Hypericum Extracts in Rats and Human Volunteers A. Biber, Hartmut Fischer, Axel Römer et al. · Pharmacopsychiatry Jun 1998 214
12 Antidepressant Activity of Hypericum Perforatum and Hyperforin: the Neglected Possibility Shyam S Chatterjee, Michael Nöldner, Egon Koch et al. · Pharmacopsychiatry Jun 1998 207
13 Sample Size Recalculation in Internal Pilot Study Designs: A Review Tim Friede, Meinhard Kieser · Biometrical Journal 25 Jul 2006 205
14 Kava-kava Extract WS 1490 versus Placebo in Anxiety Disorders - A Randomized Placebo-controlled 25-week Outpatient Trial Hans‐Peter Volz, Meinhard Kieser · Pharmacopsychiatry 1997 200
15 Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia Bernd May, Stephan Köhler, B Schneider · Alimentary Pharmacology & Therapeutics 27 Dec 2000 199
16 A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimers Type Lon S. Schneider, Steven T. DeKosky, Martin Rhys Farlow et al. · Current Alzheimer Research 25 Nov 2005 184
17 Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg Horst Friedrich Herrschaft, Anatol Nacu, С А Лихачев et al. · Journal of Psychiatric Research 27 Mar 2012 181
18 Serum procalcitonin levels in bacterial and abacterial meningitis Stefan Theodor Schwarz, Markus Bertram, Stefan Schwab et al. · Critical Care Medicine Jun 2000 180
19 Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial Siegfried F. Kasper, Markus Gastpar, Walter E. Müller et al. · International Clinical Psychopharmacology 28 May 2010 174
20 Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials Serge G. Gauthier, Sandra Schlaefke · Clinical Interventions in Aging ReviewOpen access Nov 2014 174
21 Lipid microparticles as a parenteral controlled release device for peptides Helmut Reithmeier, Joachım Herrmann, Achim M. Göpferich · Journal of Controlled Release Jun 2001 172
22 A 26-Week Analysis of a Double-Blind, Placebo-Controlled Trial of the Ginkgo biloba Extract EGb 761® in Dementia Pierre L. Le Bars, Meinhard Kieser, Kurt Z. Itil · Dementia and Geriatric Cognitive Disorders 2000 165
23 Long-term treatment with Ginkgo biloba extract EGb 761 improves symptoms and pathology in a transgenic mouse model of Alzheimer’s disease Xu Liu, Wenlin Hao, Yiren Qin et al. · Brain Behavior and Immunity 27 Jan 2015 150
24 Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts Egon Koch · Phytomedicine 16 Dec 2004 150
25 Rutin is Essential for the Antidepressant Activity of Hypericum perforatum Extracts in the Forced Swimming Test Michael Nöldner, Karl Schötz · Planta Medica Jul 2002 150
26 Efficacy and safety of a once‐daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial Ralf Ihl, Natalia Yu. Bachinskaya, Amos D. Korczyn et al. · International Journal of Geriatric Psychiatry 7 Dec 2010 141
27 Lavender Oil-Potent Anxiolytic Properties via Modulating Voltage Dependent Calcium Channels Anita M. Schuwald, Michael Nöldner, Thomas Wilmes et al. · PLoS ONE Open access 29 Apr 2013 138
28 Silexan in anxiety disorders: Clinical data and pharmacological background Siegfried F. Kasper, Walter E. Müller, Hans‐Peter Volz et al. · The World Journal of Biological Psychiatry Open access 17 May 2017 137
29 Re-calculating the sample size in internal pilot study designs with control of the type I error rate Meinhard Kieser, Tim Friede · Statistics in Medicine 15 Apr 2000 133
30 Influence of the Severity of Cognitive Impairment on the Effect of the Ginkgo biloba Extract EGb 761® in Alzheimer’s Disease Pierre L. Le Bars, F.M. Velasco, James M. Ferguson et al. · Neuropsychobiology 2002 132
31 Development and characterization of lipid microparticles as a drug carrier for somatostatin Helmut Reithmeier, Joachım Herrmann, Achim M. Göpferich · International Journal of Pharmaceutics May 2001 131
32 A randomized placebo‐controlled trial on the effects of Menthacarin, a proprietary peppermint‐ and caraway‐oil‐preparation, on symptoms and quality of life in patients with functional dyspepsia G. Rich, Ayesha Shah, Natasha A. Koloski et al. · Neurogastroenterology & Motility 10 Jul 2017 128
33 Simple procedures for blinded sample size adjustment that do not affect the type I error rate Meinhard Kieser, Tim Friede · Statistics in Medicine 14 Nov 2003 128
34 Ginkgo biloba extract EGb 761®, donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: A randomised, double-blind, exploratory trial S. Yancheva, Ralf Ihl, Gabriela Dobromirova Nikolova et al. · Aging & Mental Health Mar 2009 127
35 Ginkgo biloba Extract EGb 761® in Dementia: Intent-to-treat Analyses of a 24-week, Multi-center, Double-blind, Placebo-controlled, Randomized Trial S. Kanowski, Robert A. Hoerr · Pharmacopsychiatry Nov 2003 127
36 Efficacy and Tolerability of a Once Daily Formulation of Ginkgo biloba Extract EGb 761® in Alzheimer's Disease and Vascular Dementia: Results from a Randomised Controlled Trial Ralf Ihl, Michael Tribanek, Natalia Yu. Bachinskaya et al. · Pharmacopsychiatry Open access 15 Nov 2011 122
37 Ginkgo biloba special extract EGb 761® in generalized anxiety disorder and adjustment disorder with anxious mood: A randomized, double-blind, placebo-controlled trial Helmut Woelk, K. Arnoldt, Meinhard Kieser et al. · Journal of Psychiatric Research 4 Jul 2006 120
38 Inference on Multiple Endpoints in Clinical Trials with Adaptive Interim Analyses Meinhard Kieser, Péter Bauer, Walter Lehmacher · Biometrical Journal Jun 1999 118
39 Pharmacological profile of extracts of Pelargonium sidoides and their constituents Herbert Kolodziej, Oliver Kayser, Oliver A. Radtke et al. · Phytomedicine 2003 116
40 Efficacy and safety of Ginkgo biloba extract EGb 761 ® in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo‐controlled, double‐blind, multi‐center trial Gavrilova Si, Ulrich W. Preuss, J. W. M. Wong et al. · International Journal of Geriatric Psychiatry Open access 16 Mar 2014 114
41 Tannins from Hamamelis virginiana Bark Extract: Characterization and Improvement of the Antiviral Efficacy against Influenza A Virus and Human Papillomavirus Linda L. Theisen, Clemens A. J. Erdelmeier, Gilles A. Spoden et al. · PLoS ONE Open access 31 Jan 2014 112
42 Bilobalide, a constituent of Ginkgo biloba, inhibits NMDA-induced phospholipase A2 activation and phospholipid breakdown in rat hippocampus Oksana Weichel, Michael Hilgert, Shyam S Chatterjee et al. · Naunyn-Schmiedeberg s Archives of Pharmacology Dec 1999 111
43 Plasma Levels and Distribution of Flavonoids in Rat Brain after Single and Repeated Doses of StandardizedGinkgo bilobaExtract EGb 761® Laura Rangel-Ordóñez, Michael Nöldner, Manfred Schubert‐Zsilavecz et al. · Planta Medica 19 May 2010 108
44 Superior efficacy of St John's wort extract WS®5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298] Siegfried F. Kasper, Ion‐George Anghelescu, Armin Szegedi et al. · BMC Medicine Open access 23 Jun 2006 107
45 Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: a consensus report Régis Bordet, Ralf Ihl, Amos D. Korczyn et al. · BMC Medicine Open access 24 May 2017 106
46 Hyperforin, Possibly the Major Non-Nitrogenous Secondary Metabolite of Hypericum perforatum L. C. A. J. ERDELMEIER · Pharmacopsychiatry Jun 1998 104
47 Treatment effects of Ginkgo biloba extract EGb 761® on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials Egemen Savaskan, Heiko Mueller, Robert A. Hoerr et al. · International Psychogeriatrics ReviewOpen access 21 Sep 2017 103
48 Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761) S. Høyer, Heinrich Lannert, Michael Nöldner et al. · Journal of Neural Transmission Book chapter 15 Feb 1999 103
49 A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children Sylke-Monina Müller, Stephan Klement · Phytomedicine 20 Feb 2006 103
50 In vitro evaluation of the cytotoxic potential of alkylphenols from Ginkgo biloba L. Helke Hecker, Reiner Johannissón, Egon Koch et al. · Toxicology Aug 2002 103

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.